Impact of Diabetes on Survival and Right Ventricular Compensation in Pulmonary Arterial Hypertension

Insulin resistance is highly prevalent in pulmonary arterial hypertension (PAH) patients. However, the long-term impact of diabetes mellitus (DM) on survival in PAH is unclear. Insulin resistance and DM are associated with left ventricular steatosis and dysfunction, but whether the right ventricle (RV) might be affected by DM in PAH is unknown. We hypothesized that PAH patients with DM would have worse survival than PAH patients without DM and that this would be due to impaired RV compensation. From a large registry of PAH patients at our institution, we analyzed the effect of DM on survival in patients with idiopathic or heritable PAH. Clinical and hemodynamic differences were compared between PAH patients with DM and those without DM. Twenty-nine patients with DM and 84 without DM were included. Gender, body mass index, PAH type and duration, and 6-minute walk distance were similar between groups. PAH patients with DM had significantly lower survival at 10 years than PAH patients without DM. Right atrial pressure, pulmonary arterial pressure, and cardiac output did not differ significantly between the two groups. However, right ventricular stroke work index (RVSWI) was lower in the PAH DM group than in the no-DM patients. Among PAH patients with DM, patients who died had a lower RVSWI than survivors. In conclusion, survival in PAH patients with DM was reduced compared to that of patients without DM; impaired RV compensation may underlie this finding. Further study is needed to understand this effect.

[1]  M. Gatzoulis,et al.  [Updated clinical classification of pulmonary hypertension]. , 2014, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[2]  A. Bersten,et al.  Oh's intensive care manual , 2014 .

[3]  J. Newman,et al.  Shorter Survival in Familial versus Idiopathic Pulmonary Arterial Hypertension is Associated with Hemodynamic Markers of Impaired Right Ventricular Function , 2013, Pulmonary circulation.

[4]  J. Newman,et al.  Prostanoids but not oral therapies improve right ventricular function in pulmonary arterial hypertension. , 2013, JACC. Heart failure.

[5]  M. Mcgoon,et al.  Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis. , 2013, Chest.

[6]  J. Newman,et al.  Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. , 2012, American journal of respiratory and critical care medicine.

[7]  L. Gleaves,et al.  A potential role for insulin resistance in experimental pulmonary hypertension , 2012, European Respiratory Journal.

[8]  M. Schemper,et al.  Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[9]  D. Mancini,et al.  Ventricular Assist Device Implantation Corrects Myocardial Lipotoxicity, Reverses Insulin Resistance, and Normalizes Cardiac Metabolism in Patients With Advanced Heart Failure , 2012, Circulation.

[10]  M. Wilkins.  Pulmonary hypertension: the science behind the disease spectrum , 2012, European Respiratory Review.

[11]  L. Bossaert,et al.  Haemodynamic Monitoring , 1991, Drugs.

[12]  T. Rice,et al.  Unrecognized glucose intolerance is common in pulmonary arterial hypertension. , 2010, The Journal of Heart and Lung Transplantation.

[13]  R. Macallister,et al.  New perspectives for the treatment of pulmonary hypertension , 2011, British journal of pharmacology.

[14]  V. Basevi.  Diagnosis and Classification of Diabetes Mellitus , 2011, Diabetes Care.

[15]  Christopher S Coffey,et al.  Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) , 2010, Circulation.

[16]  M. Humbert,et al.  Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era , 2010, Circulation.

[17]  S. Russell,et al.  Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[18]  G. Raskob,et al.  Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. , 2010, Chest.

[19]  E. Ford,et al.  Prevalence of Diabetes and High Risk for Diabetes Using A1C Criteria in the U.S. Population in 1988–2006 , 2010, Diabetes Care.

[20]  N. Weissmann,et al.  Cellular and molecular basis of pulmonary arterial hypertension. , 2009, Journal of the American College of Cardiology.

[21]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[22]  G. Hansmann,et al.  Insulin resistance in pulmonary arterial hypertension , 2008, European Respiratory Journal.

[23]  Jeffrey L. Anderson,et al.  ACCF/AHA Expert Conseusus Document , 2009 .

[24]  J. Bronzwaer,et al.  Diastolic Stiffness of the Failing Diabetic Heart: Importance of Fibrosis, Advanced Glycation End Products, and Myocyte Resting Tension , 2008, Circulation.

[25]  G. Hansmann,et al.  An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. , 2008, The Journal of clinical investigation.

[26]  J. Knuuti,et al.  Myocardial fatty acid metabolism and cardiac performance in heart failure , 2008, Current cardiology reports.

[27]  G. Rossi,et al.  Diagnosis and Classification of Diabetes Mellitus The information that follows is based largely on the reports of the Expert Committee on the Diagnosis and Classification of Diabetes (Diabetes Care 20:1183–1197, 1997, and Diabetes Care 26:3160–3167, 2003). , 2008, Diabetes Care.

[28]  Amy L. Seybert,et al.  Evidence-based pharmacologic management of pulmonary arterial hypertension. , 2007, Clinical therapeutics.

[29]  Ahmad Y. Sheikh,et al.  Pulmonary Arterial Hypertension Is Linked to Insulin Resistance and Reversed by Peroxisome Proliferator–Activated Receptor-&ggr; Activation , 2007 .

[30]  Paul Sorajja,et al.  Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension. , 2006, Journal of the American College of Cardiology.

[31]  J. Loscalzo,et al.  Pulmonary arterial hypertension , 2006, The New England journal of medicine.

[32]  D. Levy,et al.  Impact of Glucose Intolerance and Insulin Resistance on Cardiac Structure and Function: Sex-Related Differences in the Framingham Heart Study , 2003, Circulation.

[33]  A. Wakatsuki,et al.  Statin attenuates increase in C-reactive protein during estrogen replacement therapy in postmenopausal women. , 2002, Circulation.

[34]  Kiyotaka Fukamachi,et al.  Predictors of Severe Right Ventricular Failure After Implantable Left Ventricular Assist Device Insertion: Analysis of 245 Patients , 2002, Circulation.

[35]  K. Ohmori,et al.  Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. , 2000, Circulation.

[36]  E H Bergofsky,et al.  Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .

[37]  D A Rickaby,et al.  Pulmonary vascular compliance and viscoelasticity. , 1986, Journal of applied physiology.

[38]  E. Wood,et al.  Cardiac output and related measurements and pressure values in the right heart and associated vessels, together with an analysis of the hemo-dynamic response to the inhalation of high oxygen mixtures in healthy subjects. , 1958, The Journal of laboratory and clinical medicine.